This study identified ten potential targets for the treatment of T2DM combined with CRC using GQD, among which GSR and MAPK9 were aberrantly expressed in both T2DM and CRC and significantly associated with CRC prognosis. This evidence concerns the gene MAPK9 and colorectal carcinoma.